Core Viewpoint - Merck's initiation of global Phase I clinical trials for the small molecule oral GLP-1 candidate MK-4082 represents a strategic move to regain market share in metabolic diseases post-DPP-4 era, focusing on broader health issues beyond glucose control [4][7]. Group 1: Merck's Strategy and Market Position - The collaboration between Merck and domestic company Haosen Pharmaceutical involves a clear financial structure, with Haosen receiving an upfront payment of $112 million and potential milestone payments up to $1.9 billion, along with revenue-sharing arrangements [6]. - Merck's choice to pursue small molecules instead of injectable large molecules is driven by the competitive landscape, where established players have set high clinical data standards and built extensive supply chains [7]. - The oral GLP-1 approach is seen as more scalable and suitable for large-scale commercialization, aligning with Merck's capabilities in managing broad indications [7]. Group 2: Industry Trends and Competitor Strategies - Major competitors like Novo Nordisk and Eli Lilly are fully engaged in the market with a comprehensive approach, including injectables and oral formulations, while focusing on supply capabilities and pricing strategies [8]. - Other companies, such as Roche and AstraZeneca, are diversifying their strategies, with Roche acquiring assets to enhance its portfolio and AstraZeneca pursuing both small molecule oral GLP-1 and multi-target approaches [9][10]. - Pfizer's strategy involves acquiring new generation long-acting assets and small molecule projects to mitigate risks associated with single project failures [9]. Group 3: Implications for Chinese Pharmaceutical Companies - The significance of MK-4082 extends to Chinese innovative drug companies, as the focus shifts from single-target me-too drugs to those with platform value, emphasizing small molecules, dual or multi-targets, and ultra-long-acting formulations [11]. - The market will closely monitor MK-4082's Phase I results for pharmacokinetics and tolerability, as well as Merck's potential to expand its asset portfolio with complementary mechanisms [11].